Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Pridopidine: Overview of … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

Forskningsöversiktsartikel
Författare Susanna Waters
J. Tedroff
Henrik Ponten
Daniel Klamer
C. Sonesson
N. Waters
Publicerad i Journal of Huntingtons Disease
Volym 7
Nummer/häfte 1
Sidor 1-16
ISSN 1879-6397
Publiceringsår 2018
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 1-16
Språk en
Länkar dx.doi.org/10.3233/jhd-170267
Ämnesord Huntington's disease, pridopidine, prefrontal cortex, striatum, motor control, dopamine, stabilizer, dopaminergic stabilizer pridopidine, placebo-controlled trial, rat, prefrontal cortex, immediate-early gene, arc messenger-rna, r6/2 mouse, model, in-vivo, movement-disorders, basal ganglia, antipsychotic-drugs
Ämneskategorier Farmakologi

Sammanfattning

Despite advances in understanding the pathophysiology of Huntington's disease (HD), there are currently no effective pharmacological agents available to treat core symptoms or to stop or prevent the progression of this hereditary neurodegenerative disorder. Pridopidine, a novel small molecule compound, has demonstrated potential for both symptomatic treatment and disease modifying effects in HD. While pridopidine failed to achieve its primary efficacy outcomes (Modified motor score) in two trials (MermaiHD and HART) there were consistent effects on secondary outcomes (TMS). In the most recent study (PrideHD) pridiopidine did not differ from placebo on TMS, possibly due to a large enduring placebo effect. This review describes the process, based on in vivo systems response profiling, by which pridopidine was discovered and discusses its pharmacological profile, aiming to provide a model for the system-level effects, and a rationale for the use of pridopidine in patients affected by HD. Considering the effects on brain neurochemistry, gene expression and behaviour in vivo, pridopidine displays a unique effect profile. A hallmark feature in the behavioural pharmacology of pridopidine is its state-dependent inhibition or activation of dopamine-dependent psychomotor functions. Such effects are paralleled by strengthening of synaptic connectivity in cortico-striatal pathways suggesting pridopidine has potential to modify phenotypic expression as well as progression of HD. The preclinical pharmacological profile is discussed with respect to the clinical results for pridopidine, and proposals are made for further investigation, including preclinical and clinical studies addressing disease progression and effects at different stages of HD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?